期刊
LEUKEMIA & LYMPHOMA
卷 59, 期 7, 页码 1634-1643出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2017.1397661
关键词
Adult acute lymphoblastic leukemia; Escherichia coli asparaginase; native; pegylated; efficacy; toxicity
资金
- Fondo de Investigaciones Sanitarias [PI10/01417]
- RTICC, Instituto de Salud Carlos III [RD12/0036/0029]
- CERCA Program, Generalitat de Catalunya, Spain [2014 SGR225(GRE)]
- 'La Caixa' Foundation
Native or pegylated (PEG) asparaginase (ASP) are commonly used in treatment of acute lymphoblastic leukemia (ALL), but have been scarcely compared in the same trial in adult patients. Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL. Ninety-one patients received native ASP and 35 PEG-ASP in induction. No significant differences were observed in complete remission, minimal residual disease levels after induction and after consolidation, disease-free survival, and overall survival. No significant differences in grades 3-4 toxicity were observed in the induction period, although a trend for higher hepatic toxicity was observed in patients receiving PEG-ASP. In this trial the type of ASP did not influence patient response and outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据